Unity Biotechnology (NASDAQ:UBX) Posts Earnings Results, Beats Expectations By $0.08 EPS

Unity Biotechnology (NASDAQ:UBX) issued its earnings results on Friday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.08, Zacks reports.

Unity Biotechnology Stock Down 4.5 %

Shares of Unity Biotechnology stock traded down $0.08 during trading on Friday, reaching $1.68. The company’s stock had a trading volume of 48,519 shares, compared to its average volume of 298,715. Unity Biotechnology has a 52 week low of $0.94 and a 52 week high of $3.10. The firm has a market cap of $28.31 million, a PE ratio of -1.28 and a beta of 1.02. The business’s 50-day moving average price is $1.82 and its 200-day moving average price is $1.50.

Wall Street Analyst Weigh In

Separately, Chardan Capital began coverage on shares of Unity Biotechnology in a research note on Friday, January 10th. They set a “buy” rating and a $6.00 target price for the company.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.